Trials / Completed
CompletedNCT02256189
Sitagliptin and Glucagon Counterregulation
The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Lund University · Academic / Other
- Sex
- All
- Age
- 65 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
Detailed description
The glucagon response to mild (3.0 mmol/l) hypoglycemia with and without DPP-4 inhibition by sitagliptin will be evaluated in elderly subjects with metformin treated type 2 diabetes to explore whether DPP-4 inhibition affects glucagon counter-regulation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | Sitagliptin 100 mg daily |
| DRUG | Placebo | Placebo one tablet daily |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2014-10-03
- Last updated
- 2019-02-20
- Results posted
- 2019-02-20
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT02256189. Inclusion in this directory is not an endorsement.